Analyst Ratings For Harvard Bioscience (NASDAQ:HBIO)
Today, Benchmark raised its price target on Harvard Bioscience (NASDAQ:HBIO) to $10.00 per share.
Some recent analyst ratings include
- 11/17/2016-Singular Research initiated coverage with a Buy rating.
Recent Insider Trading Activity For Harvard Bioscience (NASDAQ:HBIO)
Harvard Bioscience (NASDAQ:HBIO) has insider ownership of 9.80% and institutional ownership of 61.68%.
- On 6/12/2017 Jeffrey Duchemin, CEO, bought 22,000 with an average share price of $2.76 per share and the total transaction amounting to $60,720.00.
- On 6/8/2017 James W. Green, Director, bought 7,712 with an average share price of $2.55 per share and the total transaction amounting to $19,665.60.
- On 5/26/2017 Robert E. Gagnon, CFO, bought 1,000 with an average share price of $2.33 per share and the total transaction amounting to $2,330.00.
- On 5/25/2017 Earl R. Lewis, Director, bought 12,238 with an average share price of $2.35 per share and the total transaction amounting to $28,759.30.
- On 5/24/2017 Earl R. Lewis, Director, bought 10,000 with an average share price of $2.38 per share and the total transaction amounting to $23,800.00.
- On 2/7/2017 David Green, Director, sold 3,239 with an average share price of $3.25 per share and the total transaction amounting to $10,526.75.
- On 2/6/2017 David Green, Director, sold 1,288 with an average share price of $3.25 per share and the total transaction amounting to $4,186.00.
Recent Trading Activity for Harvard Bioscience (NASDAQ:HBIO)
Shares of Harvard Bioscience closed the previous trading session at 4.25 up +0.35 8.97% with 4.199999809265137 shares trading hands.